During UK Prime Minister Keir Starmer’s visit to China on Jan. 29, AstraZeneca announced a massive new commitment: more than 100 billion yuan (about $14 billion) will be invested in China by 2030. The money will fund new factories, expand existing production lines, and set up a second strategic research centre in Beijing. The goal is to tap China’s strong scientific talent and advanced manufacturing capabilities to develop next‑generation medicines, especially in hot areas like cell therapy and radioligand therapy for cancer, blood disorders and autoimmune diseases. AstraZeneca’s global chief Pascal Soriot said the investment marks a “new chapter” for the company in China, which is now a key driver of global health innovation. The plan builds on a $2.5 billion pledge made last March for a sixth global R&D hub in the capital, and follows a series of joint projects with Chinese partners. By covering the whole drug‑development chain—from discovery to clinical trials to manufacturing—AstraZeneca hopes to bring breakthrough treatments to Chinese patients faster and export Chinese scientific breakthroughs worldwide. The move also makes AstraZeneca the first multinational pharma to have end‑to‑end cell‑therapy capabilities on Chinese soil.
Read moreA wave of fresh research is reshaping how doctors think about clogged arteries. Scientists at West China Hospital discovered that gentle pulses of electromagnetic fields can calm the inflammation that fuels plaque buildup, offering a non‑drug way to slow atherosclerosis. In Shandong, a team uncovered a natural “brake” inside immune cells—an enzyme called TRIM31—that blocks a harmful receptor (LOX‑1) and reduces plaque‑forming cholesterol. Meanwhile, everyday items are turning out to be hidden hazards: tiny plastic particles from take‑out containers and non‑stick cookware not only worsen artery disease but also invade male reproductive organs. On the high‑tech front, researchers reviewed how nanomaterials can be engineered to target unstable plaques, turning invisible particles into precise medicines. A separate study identified a protein, GPSM1, that nudges immune cells toward inflamed arteries, revealing another drug target. In a striking discovery, a circular RNA (sno‑circCNOT1) was shown to amplify inflammation by hijacking nuclear scaffolding proteins, suggesting a novel epigenetic route to treat heart disease. Finally, a Chinese‑U.S. collaboration built probiotic bacteria wrapped in nanoparticles to lower the gut‑derived molecule TMAO, cutting plaque formation from the inside out. Experts warn that traditional animal models fall short, urging the use of multi‑omics data and global collaboration to bring these breakthroughs from the lab to the clinic.
Read more